exRNAdisease

General Information

Database ID:

exR0080581

RNA Name:

RPL18A

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

17859910

End Site(bp):

17864153

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AL928654.3	chr14	105487199	105492267	+
ALDOA	chr16	30064164	30070457	+
AC073508.2	chr17	40627356	40665141	-
ADGRV1	chr5	90529344	91164437	+
ACAA2	chr18	49782164	49813953	-
AKT1	chr14	104769349	104795751	-
AGPAT5	chr8	6708642	6761503	+
ADD1	chr4	2843857	2930076	+
ABCC10	chr6	43427366	43450427	+
ACTB	chr7	5527148	5563784	-
AC010422.3	chr19	12643831	12648397	-
ABHD5	chr3	43690108	43734371	+
ADAM10	chr15	58588809	58749791	-
ACTN4	chr19	38647649	38731589	+
AASS	chr7	122073549	122144255	-
AGO2	chr8	140520156	140635633	-
AC008982.1	chr19	38817471	38840178	-
ACSF3	chr16	89088375	89164121	+
AHCY	chr20	34280268	34311802	-
ACLY	chr17	41866917	41930542	-
AL359922.1	chr9	21802636	22029594	+
AC104109.3	chr5	134167170	134226071	-
AL358113.1	chr9	69035747	69255187	+
ADAMTS10	chr19	8580240	8610735	-
AC093525.2	chr16	2496032	2520218	+
AC004922.1	chr7	99325879	99394653	+
ABRAXAS2	chr10	124801819	124836667	+
ACADVL	chr17	7217125	7225266	+
AL022318.4	chr22	39014363	39033276	+
AC093525.1	chr16	2513965	2527955	+

miRNA targets:

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC245297.2	chr1	149264252	149264816	+
AD000090.1	chr19	35557956	35581954	+
AL021154.1	chr1	23549139	23550915	-
AL117378.1	chr6	131901963	131920565	+
AL137782.1	chr13	75549773	75807120	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference